A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer

  title={A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer},
  author={Thai H. Ho and Rafael N{\'u}{\~n}ez-Nateras and Yue‐xian Hou and Alan H. Bryce and Donald W. Northfelt and Amylou C. Dueck and Bryan Y. Wong and Melissa L. Stanton and Richard W. Joseph and Erik P. Castle},
  journal={Clinical Genitourinary Cancer},

Figures and Tables from this paper

Raloxifene: Promises and Challenges as a Drug Treatment for Castrate Resistant Prostate Cancer
Raloxifene, a SERM, approved for the treatment of osteoporosis in post-menopausal women, exhibits potent anti-cancer activity in in vitro and in vivo models of CRPC, but poor bioavailability, extensive metabolism, and poor water solubility have reduced its efficacy in animal studies and clinical trials.
A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation
The estrogen signaling pathway has been reported to modulate prostate cancer (PCa) progression through the activity of estrogen receptors α and β (ERα and ERβ). Given that selective estrogen receptor
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
The suitability of ADT alone or EAB for individuals may be evaluated by making clinical decisions on the basis of information obtained from RT-PCR, gene-panel, or liquid biopsy to create a “personalized medicine’ or “precision medicine”.
Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment
  • D. Tong
  • Biology
    Journal for ImmunoTherapy of Cancer
  • 2022
It is demonstrated that immunotherapy-based strategies combined with SERMs may be an option for the future of PC-targeting therapy.
Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa
The repositioning of these two well-known drugs currently in clinical use, raloxifene and N-acetylcysteine, to counteract fibrosis and inflammation in RDEB is proposed, suggesting that these findings may also be relevant for other diseases in which fibrosis is an important pathophysiological event.
Age-and Region-Dependent Disposition of Raloxifene in Rats.
Findings suggested that raloxifene metabolism in the duodenum was significantly slower at young age in rats, which increased the oral bioavailability of ral oxifene.


Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
It is demonstrated that the mixed estrogen agonist/antagonist, raloxifene, induces apoptosis in androgen-independent human prostate cancer cell lines.
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
To determine, in preclinical in vivo animal and in clinical studies, whether raloxifene affects prostate cell differentiation, proliferation and carcinogenesis, and in the pilot phase II clinical trial, the response rate and duration of patients with AIPC treated with a daily oral dose of ralOXifene.
Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptorα and β
It is demonstrated that RAL affected both transcriptional regulation and non‐genomic signals, which resulted in the modulation of multiple signaling pathways of apoptosis and of cell cycle progression, which suggest that Ral effects on PC growth control in vitro are cell‐specific, depending on ERβ or ERβ/ERα relative expression levels.
Secondary hormonal therapy for advanced prostate cancer.
Effects of high dose raloxifene in selected patients with advanced breast carcinoma
Preclinical studies and preliminary clinical data in healthy women suggest that raloxifene antagonizes growth of estrogen‐dependent neoplasia.
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial
It is indicated that raloxifene treatment over 3 years not only preserves bone mass but also lowers the risk of new vertebral fractures in postmenopausal women with osteoporosis, regardless of whether they have had fractures before starting treatment.